Urovant Sciences (NASDAQ:UROV) Trading 10.1% Higher

Urovant Sciences Ltd (NASDAQ:UROV)’s share price traded up 10.1% during mid-day trading on Tuesday . The stock traded as high as $10.16 and last traded at $10.14, 127,200 shares changed hands during trading. An increase of 132% from the average session volume of 54,914 shares. The stock had previously closed at $9.21.

Several equities research analysts recently issued reports on the stock. HC Wainwright set a $28.00 price target on shares of Urovant Sciences and gave the stock a “buy” rating in a research note on Monday, October 21st. ValuEngine downgraded shares of Urovant Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Finally, Zacks Investment Research downgraded shares of Urovant Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $21.44.

The company’s 50-day moving average price is $9.60 and its two-hundred day moving average price is $8.64. The company has a market cap of $281.64 million, a P/E ratio of -2.29 and a beta of 1.66. The company has a current ratio of 6.65, a quick ratio of 6.65 and a debt-to-equity ratio of 1.83.

Urovant Sciences (NASDAQ:UROV) last released its earnings results on Tuesday, November 5th. The company reported ($0.85) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.15) by $0.30. As a group, analysts anticipate that Urovant Sciences Ltd will post -3.95 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Atria Investments LLC bought a new stake in shares of Urovant Sciences in the 2nd quarter worth about $3,420,000. Northern Trust Corp increased its position in shares of Urovant Sciences by 55.8% in the 2nd quarter. Northern Trust Corp now owns 17,164 shares of the company’s stock worth $136,000 after purchasing an additional 6,144 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Urovant Sciences by 7.3% in the 2nd quarter. Vanguard Group Inc. now owns 131,487 shares of the company’s stock worth $1,040,000 after purchasing an additional 9,000 shares during the last quarter. LVW Advisors LLC bought a new stake in shares of Urovant Sciences in the 3rd quarter worth about $372,000. Finally, Perceptive Advisors LLC increased its position in shares of Urovant Sciences by 116.7% in the 2nd quarter. Perceptive Advisors LLC now owns 1,875,426 shares of the company’s stock worth $14,835,000 after purchasing an additional 1,010,067 shares during the last quarter. 24.26% of the stock is owned by institutional investors.

About Urovant Sciences (NASDAQ:UROV)

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

Featured Story: QQQ ETF

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.